<?xml version="1.0" encoding="UTF-8"?>
<notes notes-type="version-changes">
 <sec sec-type="version-changes">
  <label>Revised</label>
  <title>Amendments from Version 1</title>
  <p>
   <list list-type="bullet">
    <list-item>
     <p>In section 1b, we have changed representation of US dollar figure to be consistent throughout the document (as per Prof Kaufmann)</p>
    </list-item>
    <list-item>
     <p>In section 2a, we: 
      <list list-type="bullet">
       <list-item>
        <p>reference Dr. Dockerell’s work</p>
       </list-item>
       <list-item>
        <p>deleted mention of anecdotal reports of teenaged boys developing disseminated BCG after chemotherapy due to lack of supporting evidence in the literature</p>
       </list-item>
       <list-item>
        <p>clarified effect of BCG in bladder cancer (as per Prof Kaufmann)</p>
       </list-item>
      </list>
     </p>
    </list-item>
    <list-item>
     <p>In section 2b, we added NCT numbers for cited studies; also done throughout the document, where NCT numbers were available (as suggested by Prof Kaufmann)</p>
    </list-item>
    <list-item>
     <p>In section 2c, we deleted mention of specific start date of study, as dates have changed subsequent to the October 2017 conference (done elsewhere in the article, as appropriate)</p>
    </list-item>
    <list-item>
     <p>In section 3c, information regarding the planned H56:IC31 trial was deleted as it was too detailed for this paper</p>
    </list-item>
    <list-item>
     <p>In section 3f, the Huang and Hsieh 2017 publication on the Vaccae vaccine was added as a reference</p>
    </list-item>
    <list-item>
     <p>In section 4h, a description of results from recently published paper by Weiner, et al (GC6-74 consortium), as well as reference to this paper, was added as per Prof Kaufmann. An older reference to the plans for this study was deleted</p>
    </list-item>
    <list-item>
     <p>In section 5f, detailed information regarding Dr. Seder’s experiments with IV BCG in rhesus was deleted as these results have not yet been published</p>
    </list-item>
    <list-item>
     <p>In section 6c, mention of the Aeras transfer of its assets to the International AIDS Vaccine Initiative, in October 2018, is made</p>
    </list-item>
    <list-item>
     <p>In section 6d, clarification of the EDCTP role is made (as per a request from the EDCTP Director of International Collaboration, Professor Ole Olesen). Specific TB vaccine trials supported by the EDCTP are also listed (as requested by Prof Kaufmann)</p>
    </list-item>
   </list>
  </p>
 </sec>
</notes>
